is semaglutide on fda shortage list Declares of Novo Nordisk's Wegovy, Ozempic Over FDA: Novo Nordisk's Ozempic and
Description
Current safety data is insufficient , and there is a potential risk to fetal development or infant health

Treatment with survodutide has not shown unexpected safety or tolerability issues
GLP-1 drugs like semaglutide slow gastric emptying as part of their mechanism to reduce hunger and food intakethis is intentional and desired in most patients

Market Share : North America and Europe collectively hold more than 70% of the market share, with the US holding the lions share
